Johnson & Johnson 과거 순이익 실적

과거 기준 점검 5/6

Johnson & Johnson은 연평균 3.6%의 비율로 수입이 증가해 온 반면, Pharmaceuticals 산업은 수입이 8.5% 증가했습니다. 매출은 연평균 1.2%의 비율로 증가했습니다. Johnson & Johnson의 자기자본이익률은 31.7%이고 순이익률은 27.3%입니다.

핵심 정보

3.63%

순이익 성장률

6.17%

주당순이익(EPS) 성장률

Pharmaceuticals 산업 성장률	5.95%
매출 성장률	1.18%
자기자본이익률	31.69%
순이익률	27.26%
다음 순이익 업데이트	21 Jan 2026

최근 과거 실적 업데이트

Recent updates

Johnson & Johnson: Dividends Don't Lie

Nov 07

Johnson & Johnson's (NYSE:JNJ) Upcoming Dividend Will Be Larger Than Last Year's

May 21

매출 및 비용 세부 내역

Johnson & Johnson가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.

순이익 및 매출 추이

NYSE:JNJ 매출, 비용 및 순이익 (USD Millions)
날짜	매출	순이익	일반관리비	연구개발비
28 Sep 25	92,149	25,119	22,743	15,711
29 Jun 25	90,627	22,661	22,211	16,991
30 Mar 25	89,331	21,810	21,906	16,915
29 Dec 24	88,821	14,066	21,952	17,232
29 Sep 24	87,696	14,767	21,290	16,414
30 Jun 24	86,576	16,382	21,050	14,909
31 Mar 24	85,648	17,072	20,640	15,172
31 Dec 23	85,159	13,326	20,166	15,085
01 Oct 23	83,703	12,421	19,648	14,315
02 Jul 23	82,348	12,422	19,323	14,353
02 Apr 23	77,458	10,730	17,993	14,128
01 Jan 23	79,990	16,370	19,078	14,135
02 Oct 22	84,855	17,879	21,037	15,145
03 Jul 22	88,197	17,236	22,197	15,082
03 Apr 22	94,880	19,830	24,430	14,998
02 Jan 22	78,740	17,801	19,506	14,277
03 Oct 21	91,446	17,880	23,364	14,026
04 Jul 21	89,190	17,767	22,852	13,444
04 Apr 21	84,214	15,115	21,817	12,757
03 Jan 21	82,584	14,714	21,731	12,159
27 Sep 20	80,856	16,986	21,681	11,359
28 Jun 20	80,503	15,185	21,625	11,118
29 Mar 20	82,729	17,166	22,185	11,077
29 Dec 19	82,059	15,119	21,885	11,355
29 Sep 19	81,706	14,151	21,957	11,347
30 Jun 19	81,325	16,332	22,191	11,256
31 Mar 19	81,593	14,679	22,437	11,229
30 Dec 18	81,581	15,297	22,540	10,775
30 Sep 18	81,382	1,542	22,454	11,194
01 Jul 18	80,684	1,372	22,300	11,271
01 Apr 18	78,693	1,245	21,758	10,928
31 Dec 17	76,450	1,300	21,520	10,594
01 Oct 17	74,361	15,827	20,600	9,591
02 Jul 17	72,531	16,335	20,012	9,184
02 Apr 17	72,174	16,505	20,020	9,152
01 Jan 17	71,890	16,540	19,793	9,143
02 Oct 16	71,595	15,941	20,527	9,319
03 Jul 16	70,877	15,027	20,836	9,295
03 Apr 16	70,182	15,546	21,044	9,160
03 Jan 16	70,074	15,409	21,203	9,046
27 Sep 15	70,517	14,715	21,134	8,817
28 Jun 15	71,882	16,106	21,521	8,686
29 Mar 15	73,590	15,916	21,618	8,562
28 Dec 14	74,331	16,323	21,954	8,494

양질의 수익: JNJ는 $6.1B 규모의 큰 일회성 이익이 있어 28th September, 2025까지 지난 12개월 재무 결과에 영향을 미쳤습니다.

이익 마진 증가: JNJ의 현재 순 이익률 (27.3%)은 지난해 (16.9%)보다 높습니다.

잉여현금흐름 대비 순이익 분석

과거 순이익 성장 분석

수익추이: JNJ의 수익은 지난 5년 동안 연평균 3.6% 증가했습니다.

성장 가속화: 지난 1년간 JNJ 의 수익 증가율(69.9%)은 연간 평균(3.6%)을 초과합니다.

수익 대 산업: JNJ의 지난 1년 수익 증가율(69.9%)은 Pharmaceuticals 업계의 9.1%를 상회했습니다.

자기자본이익률

높은 ROE: JNJ의 자본 수익률(31.7%)은 높음으로 평가됩니다.

총자산이익률

투하자본수익률

우수한 과거 실적 기업을 찾아보세요

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2025/11/07 17:43
종가	2025/11/07 00:00
수익	2025/09/28
연간 수익	2024/12/29

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Johnson & Johnson는 52명의 분석가가 다루고 있습니다. 이 중 23명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
David Toung	Argus Research Company
Charles Butler	Barclays
Matthew Miksic	Barclays

Johnson & Johnson 과거 순이익 실적

과거 기준 점검 5/6

핵심 정보

최근 과거 실적 업데이트

Third quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Johnson & Johnson to Report Q4, 2025 Results on Jan 21, 2026

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Johnson & Johnson to Report Q3, 2025 Results on Oct 14, 2025

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Johnson & Johnson to Report Q2, 2025 Results on Jul 16, 2025

Recent updates

FDA Approves Darzalex Faspro for Adult Patients with High-Risk Smoldering Multiple Myeloma

Johnson & Johnson: Dividends Don't Lie

Johnson & Johnson Announces the U.S. Food and Drug Administration Approves Daratumumab and Hyaluronidase-fihj as A Single Agent Treatment for Adult Patients with High-Risk Smoldering Multiple Myeloma

Johnson & Johnson Announces U.S. Food and Drug Administration Approval of Caplyta (Lumateperone)

Johnson & Johnson Announces Week 28 Results from Phase 2b ANTHEM-UC Study of Icotrokinra

Johnson & Johnson Announces Findings from the Phase 2 Dahlias Study

Johnson & Johnson Announces New Long-Term Results from the Phase 3 ICONIC-TOTAL Studya Evaluating icotrokinra

Insider notifies of intention to sell stock

Third quarter dividend of US$1.30 announced

TECVAYLI® plus DARZALEX FASPRO® Combination Regimen Significantly Improves Progression-Free Survival and Overall Survival Versus Standard of Care

Johnson & Johnson Declares Dividend for the Fourth Quarter of 2025, Payable on December 9, 2025

Third quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Johnson & Johnson Raises Earnings Guidance for 2025

Johnson & Johnson to Showcase New Clinical and Real-World Data on Major Depressive Disorder Portfolio At 2025 ECNP Congress

New major risk - Revenue and earnings growth

Johnson & Johnson Announces TREMFYA® (Guselkumab) Is First and Only Il-23 Inhibitor to Demonstrate Sustained Clinical and Endoscopic Outcomes with A Fully Subcutaneous Regimen Through 48 Weeks in Ulcerative Colitis

Johnson & Johnson Announces U.S. Food and Drug Administration Approves Tremfya®? (Guselkumab) for the Treatment of Pediatric Plaque Psoriasis and Active Psoriatic Arritis

Johnson & Johnson Announces U.S. Approval for Subcutaneous Indication in Adults with Ulcerative Colitis

Johnson & Johnson Announces an Investigational Immune-Based Indication Regimen with TECVAYLI®? (Te) and DARZALEX FASPRO®? (Daratumumab andhyaluronidase-fihj) Demonstrated Clinical Trial

Johnson & Johnson Announces New Data from the Phase 3 ICONIC-ADVANCE 1 and 2 Studies

Johnson & Johnson to Showcase Neuropsychiatry Innovations at the 2025 Psych Congress Annual Meeting

Johnson & Johnson Announces U.S. Food and Drug Administration Approves Inlexzo™? (Gemcitabine Intervesical System) Set to Transform How Certain Bladder Cancersare Treated

Johnson & Johnson Elects John Morikis to its Board of Directors and Audit Committee and Compensation & Benefits Committee

Johnson & Johnson Announces Data Publishes in the New England Journal of Medicine Demonstrate RYBREVANT (Amivantamab-Vmjw) Plus LAZCLUZE (Lazertinib) Is Re-Setting Survival Expectations in First-Line EGFR-Mutated Lung Cancer

Johnson & Johnson Announces New Analyses from the Phase 3 Mariposa Study Showing That First-Line Treatment with RYBrevant (Lazertinib) Plus Lazertinib

Johnson & Johnson to Report Q4, 2025 Results on Jan 21, 2026

Johnson & Johnson Unveils Results from the Varipure Substudy of Secure, a Real-World Study on Varipure™? Platform, at 2025 European Society of Cardiology (ESC) Congress

Johnson & Johnson Announces New Data from the DanGer Shock Randomized Control Trial, Published in the New England Journal of Medicine, Confirms the Long-Term Survival Benefit of the Impella CP Heart Pump

Upcoming dividend of US$1.30 per share

Executive VP & CFO notifies of intention to sell stock

Boston Jury Hits Johnson & Johnson with Record $42 Million Verdict in Asbestos Baby Powder Case

Johnson & Johnson Files with U.S. FDA to Include New Evidence in TREMFYA®? (Guselkumab) Label as the Only IL-23 Inhibitor to Demonstrate Significant Inhibitor to Demonstrate Significant Inhibitor of Joint Structural Damage in Active Psoriatic Arthritis

New minor risk - Financial position

Johnson & Johnson Showcases Latest Advancements in Alzheimer's Research At AAIC 2025

New major risk - Revenue and earnings growth

Johnson & Johnson Announces Submission of New Drug Application to the U.S. Food and Drug Administration

Insider recently sold US$3.1m worth of stock

Insider notifies of intention to sell stock

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Johnson & Johnson Receives U.S. Fda Priority Review for Tar-200 Nda in High-Risk Non-Muscle Invasive Bladder Cancer

New major risk - Revenue and earnings growth

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2025, Payable on September 9, 2025

Johnson & Johnson Announces the Submission of A Supplemental New Drug Application to the U.S. Food and Drug Administration Based Upon Long-Term Data Evaluating the Safety and Efficacy of Caplyta (Lumateperone) for the Prevention of Relapse in Schizophrenia

Johnson & Johnson Announces New Data from an Indirect Treatment Comparison

Johnson & Johnson Hit with $8 Million Verdict in Massachusetts Mesothelioma Talc Lawsuit

Johnson & Johnson's Dual-Targeting CAR T-Cell Therapy Shows Encouraging First Results in Large B-Cell Lymphoma

Johnson & Johnson Announces New Data Showing TREMFYA® Significantly Inhibits Progression of Joint Structural Damage in Active Psoriatic Arthritis

Johnson & Johnson Appoints Daniel Pinto to the Board of Directors, Effective July 1, 2025

Johnson & Johnson Announces Data from Two Studies Highlighting DARZALEX FASPRO® (Daratumumab and Hyaluronidase-Fihj)

Johnson & Johnson Unveils First-In-Human Results for Pasritamig, Showing Early Anti-Tumor Activity in Prostate Cancer

Johnson & Johnson to Report Q3, 2025 Results on Oct 14, 2025

Johnson & Johnson's (NYSE:JNJ) Upcoming Dividend Will Be Larger Than Last Year's

Johnson & Johnson Announces U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Approves the Approval of the Benefit-Risk Profile of Single- Agent Darzalex Faspro®?

Upcoming dividend of US$1.30 per share

Jury Orders Johnson & Johnson to Pay $3 Million in Mesothelioma Death of New Orleans Woman

Johnson & Johnson Announces New Data from the Phase 3 ASTRO Study Evaluating TREMFYA (Guselkumab) Subcutaneous (SC) Induction Therapy in Adults with Moderately to Severely Active Ulcerative Colitis (UC)

Johnson & Johnson (NYSE:JNJ) Is Increasing Its Dividend To $1.30

Johnson & Johnson Announces Retirement of D. Adamczyk from the Board of Directors, May 31, 2025

Johnson & Johnson Receives FDA Approval for IMAAVY™? (Nipocalimab-Aahu)

Johnson & Johnson Announces New Data from Cohort 2 of the Pivotal Phase 2b SunRISe-1 Study Evaluating TAR-200

Johnson & Johnson Just Proved The Bears Wrong Again

Consensus EPS estimates increase by 11%

Johnson & Johnson Unveils Highly Anticipated and Potential Practice-Changing Data in Bladder Cancer Treatment At American Urological Association

Johnson & Johnson (NYSE:JNJ) Is Paying Out A Larger Dividend Than Last Year

First quarter dividend increased to US$1.30

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Johnson & Johnson Increases Quarterly Dividend, Payable on June 10, 2025

Johnson & Johnson Announces New Icotrokinra (Jnj-2113) Data from A Subgroup Analysis of Iconic-Leada

Johnson & Johnson Highlights New Data That Showcases the Strength of Nipocalimab, Demonstrating Long-Term Sustained Disease Control in Adults Living with Generalized Mg (gMG)